sub:assertion {
  d:DB08879 v:identifier "DB08879" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB08879" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB08879> ;
    dv:drugbank-id "DB08879" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:92:44> ;
    dv:x-cas <http://bio2rdf.org/cas:356547-88-1> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D03068> ;
    dv:x-ndc <http://bio2rdf.org/ndc:49401-101-01> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Belimumab> ;
    dct:description "Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain."@en ;
    dct:identifier "drugbank:DB08879" ;
    dct:title "Belimumab"@en ;
    a dv:Drug ;
    rdfs:label "Belimumab [drugbank:DB08879]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB08879> , <http://www.drugs.com/ppa/belimumab.html> , <http://www.rxlist.com/benlysta-drug.htm> .
}